Drug Trial Radar · NCT07459556
A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Mar 2026
Primary completion
Dec 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- Chengdu Kangnuoxing Biopharma,Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.
Conditions
- SAR
Interventions
StapokibartBiological
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence rate of adverse reactions (ADR).Time frame: From enrollment to the end of treatment at 10 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, CMU
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.